Feb 13, 2020
Sobi Publishes Report for the Fourth Quarter and Full-year 2019
Feb 04, 2020
Invitation - Presentation of Sobi's Q4/FY 2019 Results
Dec 21, 2019
FDA Grants Avatrombopag Orphan Drug Designation for the Treatment of Chemotherapy-induced Thrombocytopenia
Dec 09, 2019
Additional Analyses From Phase 3 study With Doptelet ® (avatrombopag) for the treatment of Chronic Immune Thrombocytopenia Provides Evidence of Long-term Response Rates
Dec 09, 2019
Doptelet ® (avatrombopag) Demonstrates Cost-effectiveness for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease
Dec 05, 2019
Data to be Highlighted at the American Society of Hematology 2019 Annual Meeting
Nov 10, 2019
Sobi Successfully Completes Tender Offer for All Outstanding Shares of Dova Pharmaceuticals
Oct 31, 2019
Sobi Publishes Report for Third Quarter 2019
Oct 23, 2019
Invitation - Presentation of Sobi's Q3 2019 Results
Aug 22, 2019
Sobi has Entered Into Agreement to Sell Priority Review Voucher
Jul 17, 2019
Sobi Publishes Report for Second Quarter 2019
Jul 09, 2019
Switching to Extended Half-life Prophylaxis Impacted Clinical Outcomes and Improved Quality of Life for People With Haemophilia A or B
Jul 08, 2019
Interim Data Evaluating Elocta® for Immune Tolerance Induction in People With Inhibitors and Severe Haemophilia A Shared at ISTH 2019
Jul 08, 2019
People With Haemophilia and Female Carriers in Sweden Have Higher Risk of Anxiety, Depression and Pain, Based on Treatment Patterns: Swedish Orphan Biovitrum
Jun 25, 2019
Sobi Presents Study Data Supporting Increased Possibilities and Improved Clinical Outcomes for People With Haemophilia at ISTH
Jun 18, 2019
New Data Demonstrates Impact of Emapalumab in Patients With Macrophage Activation Syndrome (MAS)
Jun 12, 2019
Sobi Strengthens Focus and Increases Investments in Late-Stage Development in Haematology and Immunology
Jun 12, 2019
Sobi Acquires Emapalumab and Related Assets
Apr 30, 2019
Sobi(TM) Appoints Amy Pott as New Head of Sobi North America
Apr 25, 2019
Sobi Publishes Report for First Quarter 2019